During the intervention in the LTCF, 78 subjects were screened for COVID-19 and 59 patients (47 women, 12 men) had positive pharyngeal swabs for SARS-CoV-2 RNA by RT-PCR and were diagnosed with Covid-19. Fifty-three patients (90%) had blood sampling during the initial screening phase. In 6 patients, blood sampling was not performed because of technical difficulties. These patients were excluded from the study. In 53 patients (11 men, 42 women) in which blood sampling was performed, the clinical variables and the results of biochemical and blood count analysis were available for evaluation and were included in the study. Seven patients (1 man, 6 women) were diagnosed with severe disease in initial triage and were immediately transferred to a hospital within the first 2 days of intervention. Remaining 45 patients (10 men, 36 women) remained under observation in LTCF and were screened for severe disease and triaged on a daily basis by the intervention team. Overall, 32 patients (6 men, 26 women) were admitted. Among these patients, 19 (2 men, 17 women) had hypoxemia required oxygen therapy, 16 patients (2 men, 14 women) were admitted to ICU, and 13 patients (2 men, 12 women) died. In 11 patients (1 man, 10 women) initially suffering from hypoxemia requiring oxygen therapy, the disease progressed, and they required intubation and mechanical ventilation. All these patients died because of severe ARDS. One male, initially suffering from hypoxemia requiring oxygen therapy died because of severe gastrointestinal bleeding from gastric adenocarcinoma. One female, initially suffering from hypoxemia requiring oxygen therapy suddenly died after short period of clinical improvement. An autopsy revealed pulmonary embolism. In hospitalized patients, various severe complications were observed. Six patients developed deep vein thrombosis, 6 developed congestive heart failure, 3 patients developed new atrial fibrillation and 5 developed acute renal failure. Baseline characteristics of patients are provided in Table
1. Major clinical findings of all enrolled patients are provided in
supplementary table. The baseline serum concentrations of IL-6, CRP, procalcitonin, urea, creatinine, fibrinogen, AST, ALT, fasting glucose, total bilirubin and neutrophil count were significantly higher, and lymphocyte and eosinophil count was significantly lower in patients who developed hypoxemia. All patients included in our study seroconverted and developed IgG antibodies within 1 month of diagnosis. The median of baseline serum concentrations of D-dimer and ferritin and a median total count of leukocytes were not significantly different among groups of patients with and without hypoxemia requiring oxygen therapy. Patients who developed hypoxemia requiring oxygen therapy were also significantly more comorbid according to the higher median Charlson Comorbidity Index (Table
1). In the ROC analysis, IL-6 was identified as more robust marker of hypoxemia development than CRP, procalcitonin, CRP, fibrinogen, ALT, AST and total bilirubin and lymphocyte, neutrophil and eosinophil blood count. However, all of these variables were associated with hypoxemia (Table
2). The cut-off of 24 pg/mL for IL-6 showed the best combination of sensitivity and specificity. In the group of all screened LTCF residents, baseline IL-6 concentration > 24 pg/mL predicted the development of hypoxemia with a sensitivity of 88% and specificity of 89%. Positive predictive value (PPV) was 83%, and negative predictive value was (NPV) of 93%. After excluding the 7 patients diagnosed with severe Covid-19 and transferred to the hospital after the initial assessment, baseline IL-6 concentration over 24 pg/mL predicted the development of hypoxemia during the daily monitoring in the LTCF with the sensitivity of 100%, specificity 89, PPV of 77%, and NPV 100% (Table
3). Baseline CRP concentration with cut-off of 24 mg/L showed sensitivity and specificity inferior to IL-6 (Table
4). In multivariate analysis, baseline IL-6 concentration > 24 pg/mL was positively associated with the risk of hypoxemia development during follow up in LTCF residents after adjustment for CRP, age, gender, and glomerular filtration rate (Table
5).
Table 1
Baseline characteristics of patients. Variables are provided as median (25th percentile, 75th percentile)
Age (years) | 81 (73, 87) | 87 (80.5, 90) | 0.056 | 0.522 |
SpO2 | 0.96 (0.95, 0.97) | 0.91 (0.86, 0.94) | < 0.0001 | 1.563 |
CCI | 5 (4, 6) | 7 (6, 8) | < 0.05 | 1.038 |
CRP (mg/L) | 8.92 (3.223, 17.943) | 70.69 (29.59, 142.46) | < 0.0001 | 1.398 |
IL-6 (pg/mL) | 12.3 (7.3, 20.5) | 43.1 (26.3, 116.7) | < 0.0001 | 1.880 |
D-dimer (mg/L) | 1.215 (0.558, 2.625) | 1.58 (0.78, 3.43) | 0.198 | 0.366 |
Fibrinogen (g/L) | 3.6 (3.3, 4.18) | 4.45 (3.825, 5.825) | < 0.05 | 0.869 |
Procalcitonine (ng/mL) | 0.02 (0.02, 0.03) | 0.132 (0.048, 0.313) | < 0.0001 | 1.791 |
Ferritin (ug/L) | 175.9 (94.13, 429.3) | 295.18 (149.79, 778.02) | 0.125 | 0.465 |
AST (ukat/L) | 0.355 (0.29, 0.533) | 0.755 (0.403, 1.12) | < 0.0001 | 1.214 |
ALT (ukat/L) | 0.25 (0.16, 0.37) | 0.35 (0.26, 0.54) | < 0.05 | 0.613 |
Sodium (mmol/L) | 140.9 (137.45, 142.675) | 139 (133.6, 145.6) | 0.830 | 0.06 |
Potasium (mmol/L) | 4.09 (3.85, 4.36) | 3.71 (3.235, 4.503) | 0.184 | 0.386 |
Glucose (mmol/L) | 4.8 (4.2, 5.4) | 5.9 (5.1, 7.1) | < 0.01 | 0.861 |
Urea (mmol/L) | 6.2 (5.4, 7.5) | 11 (6, 21.5) | < 0.01 | 0.794 |
Creatinine (umol/L) | 74.5 (59.25, 101.25) | 110.9 (73, 264) | < 0.05 | 0.729 |
Total bilirubin (umol/L) | 8.75 (6.55, 11.75) | 11.95 (9.8, 15.4) | < 0.0001 | 0.728 |
WBC (cells/mL) | 4880 (4100, 6515) | 5640 (4420, 8640) | 0.167 | 0.395 |
LBC (cells/mL) | 1565 (1045, 2083) | 860 (580, 1300) | < 0.0001 | 1.035 |
NBC (cells/mL) | 2680 (2015, 3800) | 3890 (2950, 7450) | < 0.05 | 0.816 |
MBC (cells/mL) | 490 (370, 615) | 440 (250, 680) | 0.712 | 0.107 |
EBC (cells/mL) | 110 (30, 190) | 10 (0, 30) | < 0.05 | 1.373 |
BBC (cells/mL) | 20 (10, 37) | 10 (10, 20) | 0.155 | 0.398 |
Table 2
AUC and optimal cut-offs for evaluated markers of hypoxemia requiring oxygen therapy by receiver operating characteristic curve analysis
IL-6 | 0.911 | 0.819–1 | 0.0001 |
CRP | 0.887 | 0.777–0.996 | 0.0001 |
Fibrinogen | 0.788 | 0.640–0.936 | 0.001 |
D-dimer | 5.777 | 0.409–0.745 | 0.392 |
PCT | 0.886 | 0.767–1 | 0.0001 |
Total bilirubin | 0.712 | 0.535–0.888 | 0.036 |
Creatinine | 0.644 | 0.443–0.846 | 0.152 |
AST | 0.838 | 0.701–0.975 | 0.001 |
ALT | 0.675 | 0.491–0.858 | 0.083 |
LBC | 0.777 | 0.642–0. 912 | 0.001 |
NBC | 0.728 | 0.582–0.783 | 0.007 |
EBC | 0.841 | 0.730–0.953 | 0.0001 |
Table 3
Test evaluation of baseline concentration of IL-6 > 24 pg/mL for predicting the development of hypoxemia requiring oxygen therapy during follow up after excluding patients admitted to hospital during initial triage
Sensitivity | 100.00% | 69.15–100.00% |
Specificity | 88.89% | 70.84–97.65% |
Disease prevalence | 27.03% | 13.79–44.12% |
PPV | 76.92% | 53.42–90.64% |
NPV | 100.00% | Non available |
Accuracy | 91.89% | 78.09–98.30% |
Table 4
Test evaluation of baseline concentration of CRP > 24 mg/L for predicting the development of hypoxemia requiring oxygen therapy during follow up after excluding patients admitted to hospital during initial triage
Sensitivity | 90.91% | 58.72 to 99.77% |
Specificity | 79.41% | 62.10 to 91.30% |
Disease prevalence | 24.44% | 12.88 to 39.54% |
PPV | 58.82% | 41.84 to 73.94% |
NPV | 96.43% | 80.52 to 99.44% |
Accuracy | 82.22% | 67.95 to 92.00% |
Table 5
Multivariate binary logistic regression analysis of the association of IL-6 > 24 pg/mL, CRP, glomerular filtration rate, gender, and age with the probability of development of hypoxemia requiring oxygen therapy during follow up
IL-6 > 24 pg/mL | < 0.05 | 39.741 | 1.838–859.426 |
CRP | 0.203 | 1.028 | 0.985–1.072 |
age | 0.187 | 1.133 | 0.943–1.364 |
gender (male) | 0.175 | 0.088 | 0.003–2.944 |
GFR | 0.773 | 0.979 | 0.850–1.128 |